» Articles » PMID: 25251768

Acknowledging and Allocating Responsibility for Clinical Inertia in the Management of Type 2 Diabetes in Primary Care: a Qualitative Study

Overview
Journal Diabet Med
Specialty Endocrinology
Date 2014 Sep 25
PMID 25251768
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Failure to intensify treatment in patients with Type 2 diabetes with suboptimal blood glucose control has been termed clinical inertia and has been shown to contribute to poorer patient outcomes. We aimed to identify and explore perceptions about clinical inertia from the perspective of primary healthcare providers.

Methods: A qualitative study was conducted in Leicestershire and Northamptonshire, UK. Purposive sampling was based on healthcare providers working in primary care settings with 'higher' and 'lower' target achievement based on routine data. Twenty semi-structured interviews were conducted, face-to-face or by telephone. Thematic analysis was informed by the constant comparative approach.

Results: An important broad theme that emerged during the analysis was related to attribution and explanation of responsibility for clinical inertia. This included general willingness to accept a degree of responsibility for clinical inertia. In some cases, however, participants had inaccurate perceptions about levels of target achievement in their primary care centres, as indicated by routine data. Participants sought to lessen their own sense of accountability by highlighting patient-level barriers such as comorbidities and human fallibility, and also system-level barriers, particularly time constraints. Perceptions about ways of addressing the problem of clinical inertia were not seen as straightforward, further emphasizing a complex and cumulative pattern of barriers.

Conclusions: In order to understand and address the problem of clinical inertia, provider, patient- and system-level barriers should be considered together rather than as separate issues. Acknowledgement of responsibility should be regarded positively as a motivator for change.

Citing Articles

A drug mix and dose decision algorithm for individualized type 2 diabetes management.

Nambiar M, Bee Y, Chan Y, Ho Mien I, Guretno F, Carmody D NPJ Digit Med. 2024; 7(1):254.

PMID: 39289474 PMC: 11408718. DOI: 10.1038/s41746-024-01230-5.


Trends in diabetes prevalence, awareness, treatment, and control in French-speaking Switzerland.

Pauli A, de Mestral C, Marques-Vidal P Sci Rep. 2024; 14(1):4839.

PMID: 38418618 PMC: 10902360. DOI: 10.1038/s41598-024-54856-6.


Therapeutic Inertia in the Management of Type 2 Diabetes: A Narrative Review.

Rodriguez P, San Martin V, Pantalone K Diabetes Ther. 2024; 15(3):567-583.

PMID: 38272993 PMC: 10942954. DOI: 10.1007/s13300-024-01530-9.


Study protocol: glycaemic outcomes in people with type 2 diabetes initiating continuous glucose monitoring: the 2GO-CGM study.

Lever C, Williman J, Boucsein A, Watson A, Sampson R, Sergel-Stringer O J Diabetes Metab Disord. 2023; 22(2):1779-1792.

PMID: 37969919 PMC: 10638210. DOI: 10.1007/s40200-023-01244-y.


Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A Systematic Review.

Almigbal T, Alzarah S, Aljanoubi F, Alhafez N, Aldawsari M, Alghadeer Z Medicina (Kaunas). 2023; 59(1).

PMID: 36676805 PMC: 9866102. DOI: 10.3390/medicina59010182.